IDWeek 2018 — Efficacy and safety data for newly FDA-approved omadacycline

  • Emily Willingham, PhD
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.


  • Omadacycline’s in vivo efficacy is unaffected by tetracycline-resistance mechanisms of tetracycline-nonsusceptible pathogens from acute skin and skin structure infection (ABSSSI) and community-acquired bacterial pneumonia (CABP).
  • In addition to these efficacy results from the OPTIC and OASIS 1 and OASIS 2 trials, an integrated analysis of the OASIS trials focused on ABSSSI shows omadacycline effectiveness, safety, and tolerability.

Why this matters

  • The FDA approved omadacycline for CAPB and ABSSSI in early October.
  • The company said in a statement that omadacycline is the first and only once-daily intravenous and oral antibiotic approved for both conditions in almost 20 years.
  • The company expects it to be available in first quarter 2019.  

Key results

  • In the efficacy trials that involved molecularly characterized pathogens, 87.5% (14/16) of those treated with omadacycline in OPTIC and 100% (5/5) in the OASIS studies had clinical success.
  • The involved pathogen was Streptococcus pneumoniae.
  • Staphylococcus aureus and Escherichia coli were involved in indeterminate clinical response cases.
  • One Klebsiella pneumoniae case involved clinical failure.
  • In the integrated analysis, omadacycline performed similarly to comparator linezolid against S aureus (including methicillin-resistant S aureus), Streptococcus pyogenes, and Streptococcus anginosus.
  • Adverse event (AEs) rates were similar between the 2 (51% with omadacycline; 41% with linezolid).
  • Most frequent AEs related to treatment were nausea and vomiting.

Study design

  • The efficacy trial evaluated Gram-positive and Gram-negative isolates (24 and 17 samples, respectively): 26 from OPTIC, 10 from OASIS 1, and 5 from OASIS 2.
  • The integrated analysis involved data from OASIS 1 and OASIS 2 (oral only), with early clinical response compared between study drug and linezolid.
  • Funding: Paretek Pharmaceuticals.


  • Small sample numbers for efficacy study.
  • Conference presentation; not peer-reviewed.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.